Deciphera Pharmaceuticals Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Deciphera Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Deciphera Pharmaceuticals stock.
View analyst ratings for Deciphera Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Deciphera Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Deciphera Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Deciphera Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Deciphera Pharmaceuticals.

Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) posted its earnings results on Tuesday, August, 3rd. The company reported ($1.21) EPS for the quarter, missing analysts' consensus estimates of ($1.15) by $0.06. The company earned $23.57 million during the quarter, compared to analysts' expectations of $22.25 million. Deciphera Pharmaceuticals had a negative trailing twelve-month return on equity of 50.07% and a negative net margin of 308.58%.
View Deciphera Pharmaceuticals' earnings history.

Deciphera Pharmaceuticals' stock was trading at $44.42 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, DCPH shares have decreased by 28.5% and is now trading at $31.75.
View which stocks have been most impacted by COVID-19.

6 brokerages have issued twelve-month price targets for Deciphera Pharmaceuticals' shares. Their forecasts range from $60.00 to $78.00. On average, they expect Deciphera Pharmaceuticals' stock price to reach $69.67 in the next twelve months. This suggests a possible upside of 119.4% from the stock's current price.
View analysts' price targets for Deciphera Pharmaceuticals or view top-rated stocks among Wall Street analysts.

3 employees have rated Deciphera Pharmaceuticals CEO Steve Hoerter on Glassdoor.com. Steve Hoerter has an approval rating of 100% among Deciphera Pharmaceuticals' employees. This puts Steve Hoerter in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Deciphera Pharmaceuticals include Mawson Infrastructure Group (WIZP), Sarepta Therapeutics (SRPT), Arrowhead Pharmaceuticals (ARWR), Ultragenyx Pharmaceutical (RARE), HUTCHMED (HCM), Legend Biotech (LEGN), Blueprint Medicines (BPMC), Perrigo (PRGO), Allakos (ALLK), Cerevel Therapeutics (CERE), I-Mab (IMAB), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Arvinas (ARVN) and TG Therapeutics (TGTX).
View all of DCPH's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Deciphera Pharmaceuticals investors own include NVIDIA (NVDA), Ionis Pharmaceuticals (IONS), Vertex Pharmaceuticals (VRTX), Allena Pharmaceuticals (ALNA), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Iovance Biotherapeutics (IOVA), SCYNEXIS (SCYX), Axsome Therapeutics (AXSM) and Exelixis (EXEL).

(DCPH) raised $101 million in an IPO on Thursday, September 28th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."

Deciphera Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Jefferies Group LLC (0.00%), Redmile Group LLC (7.31%), Vanguard Group Inc. (6.77%), BlackRock Inc. (6.34%), Franklin Resources Inc. (5.27%) and State Street Corp (3.53%). Company insiders that own Deciphera Pharmaceuticals stock include Christopher John Morl, Daniel C Martin, Daniel Lee Flynn, James Arthur Bristol, Michael Douglas Taylor, Patricia L Allen and Thomas Patrick Kelly.
View institutional ownership trends for Deciphera Pharmaceuticals.

DCPH stock was sold by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Franklin Resources Inc., Price T Rowe Associates Inc. MD, FMR LLC, Wells Fargo & Company MN, Emerald Advisers LLC, Goldman Sachs Group Inc., and Redmile Group LLC. Company insiders that have sold Deciphera Pharmaceuticals company stock in the last year include James Arthur Bristol, and Michael Douglas Taylor.
View insider buying and selling activity for Deciphera Pharmaceuticals or view top insider-selling stocks.

DCPH stock was bought by a variety of institutional investors in the last quarter, including Jefferies Group LLC, Logos Global Management LP, CIBC Asset Management Inc, Armistice Capital LLC, BlackRock Inc., State Street Corp, Avoro Capital Advisors LLC, and Point72 Asset Management L.P..
View insider buying and selling activity for Deciphera Pharmaceuticals or or view top insider-buying stocks.

Shares of DCPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DCPH stock can currently be purchased for approximately $31.75.

Deciphera Pharmaceuticals has a market capitalization of $1.84 billion and generates $42.09 million in revenue each year. The company earns $-266,490,000.00 in net income (profit) each year or ($4.78) on an earnings per share basis.

Deciphera Pharmaceuticals employs 350 workers across the globe.

The official website for Deciphera Pharmaceuticals is www.deciphera.com.

Deciphera Pharmaceuticals is headquartered at 200 SMITH STREET, Waltham MA, 02451.

Deciphera Pharmaceuticals' mailing address is 200 SMITH STREET, Waltham MA, 02451. The company can be reached via phone at (781) 209-6400 or via email at [email protected]